| MEASURE TITLE |
Venous Thromboembolism Patients with Anticoagulation Overlap Therapy |
| CMS ID |
CMS73v5 |
| VERSION NUMBER |
5.1.000 |
| DEVELOPER |
The Joint Commission |
| STEWARD |
The Joint Commission |
| COPYRIGHT |
Measure specifications are in the Public Domain.LOINC(R) is a registered
trademark of the Regenstrief Institute.This material contains SNOMED Clinical
Terms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology
Standards Development Organization. All rights reserved.
|
| VALUE SETS |
-
- VALUE SET OID: 1.3.6.1.4.1.33895.1.3.0.45
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.308
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.473
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113762.1.4.1
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.264
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.134
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.266
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113762.1.4.1021.4
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.309
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.93
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.114222.4.11.3591
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113762.1.4.1110.4
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.114222.4.11.836
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113762.1.4.1045.45
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.407
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.276
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.279
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.232
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.87
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.207
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.209
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.292
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.666.5.307
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.114222.4.11.837
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
-
- VALUE SET OID: 2.16.840.1.113883.3.117.1.7.1.213
- VALUE SET VERSION DATE: 2016-04-01 00:00:00
|
| GUID |
6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7 |
| NQF NUMBER |
0373 |
| DESCRIPTION |
This measure assesses the number of patients diagnosed with confirmed VTE
who received an overlap of parenteral (intravenous [IV] or subcutaneous
[subcu]) anticoagulation and warfarin therapy. For patients who received
less than five days of overlap therapy, they should be discharged on both
medications or have a reason for discontinuation of overlap therapy. Overlap
therapy should be administered for at least five days with an international
normalized ratio (INR) greater than or equal to 2 prior to discontinuation
of the parenteral anticoagulation therapy, discharged on both medications
or have a reason for discontinuation of overlap therapy.
|
| CATEGORY |
Medication |
| IDENTIFIER |
73 |
| STATUS |
COMPLETED |
| TYPE |
PROCESS |
| MEASURE SET |
FY 2014 EH |
